Non-oral therapies burden PAH patients

Robyn Kalda
Aug 4, 2025
1 min read

This study looked at the challenges and impacts of non-oral treatments for pulmonary arterial hypertension (PAH), beyond those caused by PAH itself. They found that people taking oral-only therapies and people taking non-oral therapy had similar health, but those taking non-oral therapy had worse quality of life, as non-oral therapy interfered with daily activities.

Read the Therapeutic Advances in Respiratory Disease article

Recent Posts

Screening for PH in ILD

This study looked at how to better detect pulmonary hypertension (PH) in people with interstitial lung disease (ILD), since PH often makes breathing problems, quality of life, and survival worse. Rese

Biomarkers identified for high-altitude PH

This study looked at which proteins and metabolic biomarkers might be associated with the development of high-altitude pulmonary hypertension (PH). Looking at data from China, from rat tissues, and fr

Smoking delays PAH diagnosis, but not CTEPH

Researchers looked at whether cigarette smoking affected the diagnosis and disease progression of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension

Comments